Boehringer Ingelheim Gains Worldwide Rights to Bridge's IPF Candidate BBT-877; Deal Terminated
Boehringer Ingelheim GmbH licensed exclusive worldwide rights to Bridge Biotherapeutics Inc.'s BBT877 for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.